It suppresses stemness traits of ESCC cells by targeting the deubiquitinating enzyme (USP8), diminishes the expression of stemness-related markers such as SOX2 and NANOG, decreases the sphere-forming capacity of drug-resistant cells, and lowers the incidence of tumor formation in vivo. The gene discussed is SOX2; the disease is neoplasm.